Convergence Investment Partners’s Impax Laboratories, Inc. IPXL Stock Holding History

Convergence Investment Partners’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-84,111	Closed	-$1.99M	–	407
2016 Q3	$1.99M	Buy	84,111 +27,171	+48%	+$730K	0.29%	124
2016 Q2	$1.64M	Buy	+56,940	New	+$1.86M	0.23%	168
2014 Q2	–	Sell	-32,740	Closed	-$865K	–	453
2014 Q1	$865K	Buy	+32,740	New	+$818K	0.13%	220

Other funds holding IPXL

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hound Partners New York $799M AUM 9.54% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NTC

North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Convergence Investment Partners's IPXL Position: Q4 2016 in Review

Convergence Investment Partners sold out of Impax Laboratories, Inc. (IPXL) in Q4 2016, closing a stake of 84,111 shares — an estimated $1.99M sold.

Convergence Investment Partners first reported a position in IPXL in Q1 2014 and held it in 3 quarters. The position peaked at $1.99M in Q3 2016. 198 funds tracked by Wall St. Rank hold IPXL as of Q4 2016.

Convergence Investment Partners reported no remaining Impax Laboratories, Inc. position as of Q4 2016 after selling out during the quarter.
Convergence Investment Partners sold 84,111 Impax Laboratories, Inc. shares in Q4 2016, an estimated $1.99M.
Convergence Investment Partners first reported a position in Impax Laboratories, Inc. in Q1 2014 and held it in 3 quarters.
Convergence Investment Partners's Impax Laboratories, Inc. position peaked at $1.99M in Q3 2016.
198 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2016.

Based on Convergence Investment Partners's 13F filing for Q4 2016, filed 13 Feb 2017.